Kanuka honey versus aciclovir for the topical treatment of herpes simplex labialis: a randomised controlled trial.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
14 05 2019
Historique:
entrez: 17 5 2019
pubmed: 17 5 2019
medline: 12 5 2020
Statut: epublish

Résumé

To compare New Zealand medical grade kanuka honey with topical aciclovir for the treatment of herpes simplex labialis. Prospective parallel randomised controlled open-label superiority trial. 76 community pharmacies across New Zealand between 10 September 2015 and 13 December 2017. 952 adults randomised within the first 72 hours of a herpes simplex labialis episode. Random assignment 1:1 to either 5% aciclovir cream or medical grade kanuka honey (90%)/glycerine (10%) cream, both applied five times daily. The primary outcome was time from randomisation to return to normal skin (stage 7). Secondary outcomes included time from randomisation to stage 4 (open wound), time from stage 4 to 7, maximal pain, time to pain resolution and treatment acceptability. Primary outcome variable: Kaplan-Meier-based estimates (95% CI) for the median time in days for return to normal skin were 8 (8 to 9) days for aciclovir and 9 (8 to 9) for honey; HR (95% CI) 1.06 (0.92 to 1.22), p=0.56. There were no statistically significant differences between treatments for all secondary outcome variables. No related serious adverse events were reported. There was no evidence of a difference in efficacy between topical medical grade kanuka honey and 5% aciclovir in the pharmacy-based treatment of herpes simplex labialis. ACTRN12615000648527;Post-results.

Identifiants

pubmed: 31092654
pii: bmjopen-2018-026201
doi: 10.1136/bmjopen-2018-026201
pmc: PMC6530412
doi:

Substances chimiques

Antiviral Agents 0
Acyclovir X4HES1O11F

Banques de données

ANZCTR
['ACTRN12615000648527']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e026201

Informations de copyright

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: RB reports grants from HoneyLab, during the conduct of the study; grants and personal fees from GlaxoSmithKline, outside the submitted work. All other authors declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work; no other relationships or activities that could appear to have influenced the submitted work.

Références

JAMA Oncol. 2017 Jun 1;3(6):738-739
pubmed: 27658006
J Tradit Complement Med. 2014 Jan;4(1):24-35
pubmed: 24872930
Curr Opin Virol. 2014 Oct;8:54-61
pubmed: 25036916
Immunopharmacol Immunotoxicol. 2012 Aug;34(4):598-607
pubmed: 22212104
BMJ Clin Evid. 2009 Sep 23;2009:
pubmed: 21726482
N Z Med J. 2009 May 22;122(1295):47-60
pubmed: 19648986
Arch Virol. 2017 Sep;162(9):2539-2551
pubmed: 28547385
Arch Med Res. 2014 Jul;45(5):359-65
pubmed: 24880005
BMJ Open. 2015 Jun 24;5(6):e007651
pubmed: 26109117
Food Chem. 2017 Dec 15;237:214-224
pubmed: 28763988
Clin Trials. 2016 Apr;13(2):117-26
pubmed: 26908540
Lancet. 2005 Jan 1-7;365(9453):82-93
pubmed: 15639683
Iran J Basic Med Sci. 2013 Jun;16(6):731-42
pubmed: 23997898
Cochrane Database Syst Rev. 2015 Mar 06;(3):CD005083
pubmed: 25742878
Transl Biomed. 2012;3(2):
pubmed: 22822475
BMJ Open. 2017 Aug 3;7(8):e017766
pubmed: 28775197
Wound Repair Regen. 2014 Mar-Apr;22(2):187-92
pubmed: 24612472
J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1440-1446
pubmed: 28449377
Med Sci Monit. 2004 Aug;10(8):MT94-8
pubmed: 15278008
Antimicrob Agents Chemother. 2002 Jul;46(7):2238-43
pubmed: 12069980
Wounds. 2014 Feb;26(2):47-54
pubmed: 25860226
Ochsner J. 2012 Spring;12(1):45-56
pubmed: 22438782
J Am Acad Dermatol. 2015 Sep;73(3):525-6
pubmed: 26282802
Pharmacoeconomics. 2015 Nov;33(11):1195-214
pubmed: 26068945
Wounds. 2015 Jun;27(6):141-51
pubmed: 26061489
Antiviral Res. 2014 Nov;111:36-41
pubmed: 25218782
J Altern Complement Med. 1996 Fall;2(3):345-8
pubmed: 9395668

Auteurs

Alex Semprini (A)

Medical Research Institute of New Zealand, Wellington, New Zealand.

Irene Braithwaite (I)

Medical Research Institute of New Zealand, Wellington, New Zealand.

Nick Shortt (N)

Medical Research Institute of New Zealand, Wellington, New Zealand.

Darmiga Thayabaran (D)

Medical Research Institute of New Zealand, Wellington, New Zealand.

Melanie McConnell (M)

Victoria University of Wellington, Wellington, New Zealand.

Mark Weatherall (M)

University of Otago Wellington, Wellington, New Zealand.

Richard Beasley (R)

Medical Research Institute of New Zealand, Wellington, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH